VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2021 | DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement

Marta Vaz Batista, MD, Hospital Professor Doutor Fernando Fonseca, Amadora, Portugal, discusses the DEBBRAH trial (NCT04420598), a Phase II study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive or HER2-low expressing advanced breast cancer and central nervous system (CNS) involvement. T-DXd demonstrated preliminary efficacy with manageable toxicity in pretreated patients with HER2+ advanced breast cancer with stable and progressing brain metastases after local treatment. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter